SHINE Technologies, a next-generation fusion technology company, and SHINE Europe announced today that the Dutch government has approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.
Within this project, SHINE Europe, together with the University Medical Center Groningen (UMCG) and Delft University of Technology (TU Delft), aims to develop and realize all the technologies and facilities needed to secure the entire supply chain for terbium-based nuclear medicine. This will also involve increased cooperation with partners in the European Union. “Previous collaborations with UMCG and TU Delft have been very fruitful,” said Harrie Buurlage, general manager of SHINE Europe. “We therefore view our collaboration within the project with great confidence.”
Research shows that terbium isotopes are a potentially effective method for diagnosing and treating cancer and other diseases. But a lack of essential raw materials and complex processing technology are among the current barriers to terbium production. These obstacles can be solved by SHINE’s innovative production methods. These enable SHINE to have a vertically integrated supply chain, from raw material production through cGMP product purification.
;
